compounded semaglutide tirzepatide & 2025: Safe Use Guide FDA says 'no clinical need'

Tirzepatide, a GLP-1 and GIP receptor agonist, can influence sleep in multiple ways during weight loss therapy

If you are a female reproductive potential: Zepbound may reduce the efficacy of oral hormonal contraceptives

Those data might allow other experts to confirm or deny the studys conclusions

V., Naimi, S., Demers-Mathieu, V., Pilon, G., et al

Skin color is irrelevant to some people

Originally developed for type 2 diabetes management, Semaglutide gained widespread attention after the STEP 1 clinical trial (NEJM, 2021) demonstrated an average weight loss of 14.9% of body weight over 68 weeks at the 2.4mg weekly dose